Alzheimer’s blood tests are moving from specialist research into clinical practice after real-world evidence showed that biomarker results sharply improved diagnostic accuracy. The opportunity is substantial, but differences between assays, inappropriate screening and laboratory-quality failures could undermine confidence.
Replimune Group is awaiting a delayed FDA decision on RP1 after advisers voted that its melanoma results were clinically meaningful. Approval would create a more accessible oncolytic immunotherapy option, but regulators remain divided over whether the single-arm IGNYTE trial reliably proves RP1’s contribution.
KKR has agreed to acquire Integer Holdings in a $5.7 billion transaction, taking one of the world’s largest medical-device development and manufacturing partners private. The deal gives KKR exposure to cardiovascular, neuromodulation and cardiac-rhythm technologies, but Integer’s slowing sales and elevated debt show why operational execution will matter after the takeover.
The FDA is clarifying when one rigorous pivotal trial supported by confirmatory evidence may establish a drug’s effectiveness. The approach could shorten development in rare diseases and precision medicine, but it does not turn small, uncontrolled or statistically fragile studies into approval-ready evidence.
AbCellera will report Phase 2 ABCL635 data on Aug. 10, testing whether a long-acting NK3 antibody can reduce menopause hot flashes.
Scholar Rock shifts apitegromab’s FDA review to a second fill-finish site as its September 30 SMA decision date remains on track.
Faeth Therapeutics explains the PK/PD rationale behind PIKTOR dosing as its Phase 2 endometrial cancer trial approaches a 2026 readout.
RiboX Therapeutics has received clearance from the United States Food and Drug Administration to begin clinical testing of RXIM002, an experimental treatment designed to create temporary anti-CD19 CAR-T cells directly inside the body of a patient with autoimmune disease. The August 8, 2026 investigational new drug clearance allows RiboX Therapeutics to initiate the Phase 1
The United States Food and Drug Administration (FDA) has granted accelerated approval to Replimune Group’s Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed during a programmed death receptor-1 blocking treatment. The August 6, 2026 decision gives oncologists a new option for a difficult stage of melanoma treatment, when tumours
GRAIL, Inc. will face a potentially defining regulatory examination on September 23, 2026, when outside advisers to the United States Food and Drug Administration review the premarket approval application for its Galleri multi-cancer early detection blood test. The FDA’s Molecular and Clinical Genetics Panel is scheduled to discuss and vote on whether the available evidence